Treatment responses, survival, and causes of death in 81 patients treated with voriconazole for definite or probable central nervous system aspergillosis
Underlying condition . | No. patients . | Median duration of VRC, d (range) . | No. CR/no. PR . | No. stable/no. failure . | Median survival, d (range) . | No. patients died due to aspergillosis, (%) . | No. patients with reported survival (%) . |
|---|---|---|---|---|---|---|---|
| Hematologic malignancy | 13 | 96 (5-522) | 2/5 | 2/4 | 113 (7-759) | 4 (31) | 2 (15) |
| Other | 14 | 82 (1-946) | 2/5 | 3/4 | 130 (11-969) | 5 (36) | 6 (43) |
| Chronic immune suppression | 11 | 122 (9-1128) | 1/4 | 3/3 | 222 (10-1128) | 3 (27) | 7 (64) |
| Solid organ transplantation | 11 | 39 (7-825) | 0/4 | 2/5 | 78 (8-1245) | 7 (64) | 3 (27) |
| Stem cell transplantation | 32 | 20 (3-390) | 2/3 | 3/24 | 28 (3-689) | 18 (56) | 7 (22) |
| Total | 81 | 51 (1-1128) | 7/21 | 13/40 | 69 (3-1245) | 37 (46) | 25 (31) |
Underlying condition . | No. patients . | Median duration of VRC, d (range) . | No. CR/no. PR . | No. stable/no. failure . | Median survival, d (range) . | No. patients died due to aspergillosis, (%) . | No. patients with reported survival (%) . |
|---|---|---|---|---|---|---|---|
| Hematologic malignancy | 13 | 96 (5-522) | 2/5 | 2/4 | 113 (7-759) | 4 (31) | 2 (15) |
| Other | 14 | 82 (1-946) | 2/5 | 3/4 | 130 (11-969) | 5 (36) | 6 (43) |
| Chronic immune suppression | 11 | 122 (9-1128) | 1/4 | 3/3 | 222 (10-1128) | 3 (27) | 7 (64) |
| Solid organ transplantation | 11 | 39 (7-825) | 0/4 | 2/5 | 78 (8-1245) | 7 (64) | 3 (27) |
| Stem cell transplantation | 32 | 20 (3-390) | 2/3 | 3/24 | 28 (3-689) | 18 (56) | 7 (22) |
| Total | 81 | 51 (1-1128) | 7/21 | 13/40 | 69 (3-1245) | 37 (46) | 25 (31) |
VRC indicates voriconazole; CR, complete response; PR, partial response.